AP2006003659A0 - Azabenzofuran substituted thioureas, inhibitors ofviral replication - Google Patents

Azabenzofuran substituted thioureas, inhibitors ofviral replication

Info

Publication number
AP2006003659A0
AP2006003659A0 AP2006003659A AP2006003659A AP2006003659A0 AP 2006003659 A0 AP2006003659 A0 AP 2006003659A0 AP 2006003659 A AP2006003659 A AP 2006003659A AP 2006003659 A AP2006003659 A AP 2006003659A AP 2006003659 A0 AP2006003659 A0 AP 2006003659A0
Authority
AP
ARIPO
Prior art keywords
ofviral
replication
inhibitors
substituted thioureas
azabenzofuran
Prior art date
Application number
AP2006003659A
Inventor
Andrew Thurkauf
Dawei Chen
Avinash Phadke
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of AP2006003659A0 publication Critical patent/AP2006003659A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
AP2006003659A 2004-01-06 2005-01-05 Azabenzofuran substituted thioureas, inhibitors ofviral replication AP2006003659A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53483904P 2004-01-06 2004-01-06
PCT/US2005/000339 WO2005067900A2 (en) 2004-01-06 2005-01-05 Azabenzofuran substituted thioureas as inhibitors of viral replication

Publications (1)

Publication Number Publication Date
AP2006003659A0 true AP2006003659A0 (en) 2006-06-30

Family

ID=34794326

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003659A AP2006003659A0 (en) 2004-01-06 2005-01-05 Azabenzofuran substituted thioureas, inhibitors ofviral replication

Country Status (19)

Country Link
US (1) US7439374B2 (en)
EP (1) EP1709047B1 (en)
JP (1) JP2007517887A (en)
KR (1) KR20060121289A (en)
CN (1) CN1946720A (en)
AP (1) AP2006003659A0 (en)
AR (1) AR047367A1 (en)
AT (1) ATE479684T1 (en)
AU (1) AU2005204369B2 (en)
BR (1) BRPI0506705A (en)
CA (1) CA2552002A1 (en)
DE (1) DE602005023266D1 (en)
EA (1) EA200601281A1 (en)
IL (1) IL176486A0 (en)
NO (1) NO20062928L (en)
NZ (1) NZ548375A (en)
OA (1) OA13357A (en)
TW (1) TW200528459A (en)
WO (1) WO2005067900A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
BRPI0715714A2 (en) * 2006-08-25 2014-03-11 Wyeth Corp METHODS FOR REDUCING THE EMERGENCY FREQUENCY OF A RESISTANT TREATMENT HEPATITIS C VIRAL INFECTION TO DELAY THE EMERGENCY OF A TREATMENT RESISTANT HEPATITIS C VIRAL INFECTION TO REDUCE THE RESISTANCE LEVEL OF A VIRAL TREATMENT INFECTION TO REDUCE THE EMERGENCY OF AN HCV-796 RESISTANT HEPATITIS C VIRAL INFECTION, TO IDENTIFY AN INDIVIDUAL WITH A REDUCED PROBABILITY TO ANTI-HEPATITIS DIAGNOSTIC OR DIAGNOSTIC DIAGNOSIS MONITORING TREATMENT IN A PATIENT TO MONITOR THE TREATMENT COURSE OF HEPATITIS C VIRAL INFECTION IN A PATIENT TO PROGNOSTIC DEVELOPMENT OF A HEPATITIS C VIRAL INFECTION RESISTANT TO MONITOR THE INFECTION OF A HEPATITIS C PATIENT AND TO DIAGNOSE THE DEVELOPMENT OF A HEPATITIS VIRAL INFECTION OF TREATMENT IN A PATIENT YOU
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US7985763B2 (en) * 2007-04-10 2011-07-26 National Health Research Institutes Hepatitis C virus inhibitors
TW200848016A (en) * 2007-06-08 2008-12-16 Nat Health Research Institutes Thiourea compound and composition of treating hepatitis C virus infection
TWI361808B (en) * 2008-01-08 2012-04-11 Nat Health Research Institutes Imidazolidinone and imidazolidinethione derivatives
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP5793084B2 (en) 2008-12-23 2015-10-14 ギリアド ファーマセット エルエルシー Synthesis of purine nucleosides
BRPI0922508A8 (en) 2008-12-23 2016-01-19 Pharmasset Inc NUCLEOSID ANALOGS
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP5872539B2 (en) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー Purine nucleoside phosphoramidate
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CN102858790A (en) 2010-03-31 2013-01-02 吉利德制药有限责任公司 Nucleoside Phosphoramidates
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
PT3042910T (en) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-spiro-nucleosides for use in the therapy of hepatitis c
SG10201602044WA (en) 2011-09-16 2016-04-28 Gilead Pharmassett Llc Methods For Treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2860181B1 (en) * 2012-04-10 2019-02-13 Shanghai Yingli Pharmaceutical Co. Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition and uses thereof
CA2852867C (en) 2013-01-31 2016-12-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
MX2016002185A (en) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds.
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP4108659A1 (en) 2016-06-07 2022-12-28 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
AU2018239542C1 (en) 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1408198A (en) 1971-08-23 1975-10-01 Medizinska Akad Antiviral compositions
CN1071930A (en) 1991-07-10 1993-05-12 伊莱利利公司 Inhibitor as the human immunodeficiency virus protease who treats acquired immune deficiency syndrome (AIDS)
GB9504460D0 (en) 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives
AU3057697A (en) 1996-05-06 1997-11-26 Eli Lilly And Company Anti-viral compounds
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
KR20050065661A (en) * 2002-11-01 2005-06-29 비로파마 인코포레이티드 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
CA2506415A1 (en) * 2002-11-19 2004-06-03 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
NZ544674A (en) * 2003-07-10 2009-03-31 Achillion Pharmaceuticals Inc Substituted arylthiourea derivatives useful as inhibitors of viral replication

Also Published As

Publication number Publication date
EA200601281A1 (en) 2006-12-29
IL176486A0 (en) 2006-10-05
TW200528459A (en) 2005-09-01
EP1709047A2 (en) 2006-10-11
JP2007517887A (en) 2007-07-05
AU2005204369B2 (en) 2010-06-10
BRPI0506705A (en) 2007-05-02
WO2005067900A2 (en) 2005-07-28
AR047367A1 (en) 2006-01-18
AU2005204369A1 (en) 2005-07-28
EP1709047B1 (en) 2010-09-01
KR20060121289A (en) 2006-11-28
CN1946720A (en) 2007-04-11
ATE479684T1 (en) 2010-09-15
NZ548375A (en) 2010-07-30
NO20062928L (en) 2006-08-03
WO2005067900A3 (en) 2005-09-29
US7439374B2 (en) 2008-10-21
CA2552002A1 (en) 2005-07-28
OA13357A (en) 2007-04-13
US20050228013A1 (en) 2005-10-13
DE602005023266D1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
AP2006003659A0 (en) Azabenzofuran substituted thioureas, inhibitors ofviral replication
GB2424882B (en) Selective kinase inhibitors
EP1794137A4 (en) Specific kinase inhibitors
IL179398A0 (en) Dpp-ib inhibitors
IL190078A0 (en) Kinase inhibitors
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
ZA200705628B (en) Pyrrolopyrazoles, potent kinase inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
IL183276A0 (en) Kinase inhibitors
AP2074A (en) New 4-benzylidene-piperidin derivatives
PL1943243T3 (en) Kinase inhibitors
ZA200709269B (en) Protein kinase inhibitors
HK1100141A1 (en) Kinase inhibitors
HK1101638A1 (en) New pyridothienopyrimidine derivatives
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
GB0421355D0 (en) Inhibitors
GB0421356D0 (en) Inhibitors
GB0516967D0 (en) Inhibitors
IL189985A0 (en) Kinase inhibitors
ZA200803287B (en) Kinase inhibitors
GB0408300D0 (en) Novel inhibitors
AU2004900103A0 (en) Selective Kinase Inhibitors
ITPD20040243A1 (en) INSERT FOR SUBHEADSTANDS.